The abnormal cannabidiol analogue O-1602 reduces nociception in a rat model of acute arthritis via the putative cannabinoid receptor GPR55.

Author(s): Schuelert N, McDougall JJ

Department of Physiology & Pharmacology, University of Calgary, 3330 Hospital Drive NW, Calgary, AB T2N4N1, Canada

Subject: Arthritis View the study


Cannabinoids classically act via CB₁ and CB₂ receptors to modulate nociception; however, recent findings suggest that some cannabinoids bind to atypical receptors. One such receptor is GPR55 which is activated by the abnormal cannabidiol analogue O-1602. This study investigated whether the synthetic GPR55 agonist O-1602 can alter joint nociception in a rat model of acute joint inflammation. Acute (24 h) inflammatory joint pain was induced in male Wistar rats by intra-articular injection of 2% kaolin and 2% carrageenan.

Source: Neuroscience Letters (Price: $36)
Share Tweet

More medical studies related to Arthritis:

View all medical studies >>

Subscribe for daily cannabis news, announcements, and business insights.